Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 178 Records) |
Query Trace: BID[original query] |
---|
Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized controlled trial. Therapeutic advances in gastroenterology 2020 8 13 1756284820927306. Chen Chieh-Chang, Luo Jiing-Chyuan, Fang Yu-Jen, Lee Ji-Yuh, Kuo Chia-Chi, Yang Tsung-Hua, Chiu Min-Chin, Yu Jian-Jyun, Bair Ming-Jong, Chen Po-Yueh, Chou Chu-Kuang, Chen Chi-Yi, Chang Chi-Yang, Hsu Yao-Chun, Tseng Cheng-Hao, Hsu Wen-Feng, Hu Wen-Hao, Tsai Min-Horn, Hsieh Cheng-Lin, Chen Mei-Jyh, Shun Chia-Tung, Liu Tzeng-Ying, Lee Yi-Chia, Liou Jyh-Ming, Wu Ming-Shiang, |
Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. The oncologist 2020 12 26 (4): 290-e545. van Brummelen Emilie M J, Huijberts Sanne, van Herpen Carla, Desar Ingrid, Opdam Frans, van Geel Robin, Marchetti Serena, Steeghs Neeltje, Monkhorst Kim, Thijssen Bas, Rosing Hilde, Huitema Alwin, Beijnen Jos, Bernards Rene, Schellens J |
An Autophagy-Related Gene Signature Associated With Clinical Prognosis and Immune Microenvironment in Gliomas. Frontiers in oncology 2020 10 571189. Xu Yang, Li Renpeng, Li Xiaoxia, Dong Naijun, Wu Di, Hou Lin, Yin Kan, Zhao Chunh |
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study). ESMO open 2021 7 6 (4): 100212. Perez-Fidalgo J A, Cortés A, Guerra E, García Y, Iglesias M, Bohn Sarmiento U, Calvo García E, Manso Sánchez L, Santaballa A, Oaknin A, Redondo A, Rubio M J, González-Martín |
A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2021 5 157 21-29. Fung A S, Graham D M, Chen E X, Stockley T L, Zhang T, Le L W, Albaba H, Pisters K M, Bradbury P A, Trinkaus M, Chan M, Arif S, Zurawska U, Rothenstein J, Zawisza D, Effendi S, Gill S, Sawczak M, Law J H, Leighl N |
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma. Investigational new drugs 2021 Mar . Zauderer Marjorie G, Alley Evan W, Bendell Johanna, Capelletto Enrica, Bauer Todd M, Callies Sophie, Szpurka Anna M, Kang Suhyun, Willard Melinda D, Wacheck Volker, Varghese Anna |
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations. Investigational new drugs 2021 3 39 (5): 1324-1334. Piha-Paul Sarina A, Azaro Analía, Arkenau Hendrik Tobias, Oh Do-Youn, Galsky Matthew D, Pal Sumanta Kumar, Hamada Kensuke, He Yaohua, Yamamiya Ikuo, Benhadji Karim A, Hollebecque Antoi |
A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. Scientific reports 2021 2 11 (1): 4433. Poveda Andres, Oaknin Ana, Romero Ignacio, Guerrero-Zotano Angel, Fariñas-Madrid Lorena, Rodriguez-Freixinos Victor, Mallol Pedro, Lopez-Reig Raquel, Lopez-Guerrero Jose Anton |
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer chemotherapy and pharmacology 2021 11 89 (1): 105-115. Padda Sukhmani K, Reckamp Karen L, Koczywas Marianna, Neal Joel W, Kawashima Jun, Kong Shengchun, Huang Daniel B, Kowalski Mark, Wakelee Heather |
Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma. Cancer science 2021 1 112 (3): 1123-1131. Munakata Wataru, Shirasugi Yukari, Tobinai Kensei, Onizuka Makoto, Makita Shinichi, Suzuki Rikio, Maruyama Dai, Kawai Hidetsugu, Izutsu Koji, Nakanishi Tadashi, Shiba Sari, Hojo Seichiro, Ando Kiyos |
Identification of immune-related ferroptosis prognostic marker and in-depth bioinformatics exploration of multi-omics mechanisms in thyroid cancer. Frontiers in molecular biosciences 2022 9 9 961450. Fan Xin, Xie Fei, Zhang Lingling, Tong Chang, Zhang Zhiyu |
First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements. European journal of cancer (Oxford, England : 1990) 2022 Sep 173 238-249. Ma Yuxiang, Zhao Hongyun, Xue Jinhui, Liu Li, Yang Nong, Zhang Yang, Yang Haiyan, Hong Shaodong, Xiong Yi, Zhang Zhonghan, Zeng Liang, Pan Hui, Zhou Chunhua, Zhang Yongchang, Wang Xunqiang, Han Xi, Wan Xiaojing, Shao Yang, Liu Jingwen, Yang Yunpeng, Huang Yan, Zhao Yuanyuan, Fang Wenfeng, Li Su, Zhang |
Tacrolimus dose adjustment is not necessary in dose to dose conversion from a twice daily to a prolonged release once daily dose form. Scientific reports 2022 6 12 (1): 10051. Tiankanon Kanitha, Kerr Stephen J, Thongthip Siriwan, Udomkarnjananun Suwasin, Sodsai Pimpayao, Vorasittha Athaya, Panumatrassamee Kamol, Takkavatakarn Kullaya, Tungsanga Kriang, Eiam-Ong Somchai, Praditpornsilpa Kearkiat, Avihingsanon Yingyos, Townamchai Natavu |
Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B). Clinical cancer research : an official journal of the American Association for Cancer Research 2022 5 . Yang James Chih-Hsin, Ohe Yuichiro, Chiu Chao-Hua, Ou Xiaoling, Cantarini Mireille, Jänne Pasi A, Hartmaier Ryan J, Ahn Myung |
Cannabidiol for Functional Dyspepsia With Normal Gastric Emptying: A Randomized Controlled Trial. The American journal of gastroenterology 2022 May . Atieh Jessica, Maselli Daniel, Breen-Lyles Margaret, Torres Monique, Katzka David, Ryks Michael, Busciglio Irene, Burton Duane, Carlson Paula, Harmsen W Scott, Camilleri Micha |
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. The oncologist 2022 5 . Le Xiuning, Baik Christina, Bauman Jessica, Gilbert Jill, Brose Marcia S, Grilley-Olson Juneko E, Patil Tejas, McDermott Ray, Raez Luis E, Johnson Jennifer M, Shen Lin, Tahara Makoto, Ho Alan L, Norenberg Ricarda, Dima Laura, Brega Nicoletta, Drilon Alexander, Hong David |
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: ?Safety, Efficacy, and Biomarkers. The oncologist 2022 4 27 (5): 342-e383. Wang Yakun, Liu Tianshu, Chen Gongyan, Gong Jifang, Bai Yuxian, Zhang Tao, Xu Nong, Liu Li, Xu Jianming, He Jianxing, Liu Yunpeng, Zhang Li, Jiang Da, Wang Mengzhao, Chang Jianhua, Li Wei, Bai Chunmei, Zhou Jinghong, Wang Jian, Ren Yongxin, Zhang Liya, Su Weiguo, Liu Baorui, Shen L |
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis. Annals of oncology : official journal of the European Society for Medical Oncology 2022 12 34 (2): 152-162. Labidi-Galy S I, Rodrigues M, Sandoval J L, Kurtz J E, Heitz F, Mosconi A M, Romero I, Denison U, Nagao S, Vergote I, Parma G, Nøttrup T J, Rouleau E, Garnier G, El-Balat A, Zamagni C, Martín-Lorente C, Pujade-Lauraine E, Fiévet A, Ray-Coquard I |
CYP2C19 genotype and platelet aggregation test-guided dual antiplatelet therapy after off-pump coronary artery bypass grafting: A retrospective cohort study. Frontiers in cardiovascular medicine 2022 12 9 1023004. Yao Haoyi, Qin Kaijie, Liu Yun, Yang Yi, Zhu Jiaxi, Chen Anqing, Wang Zhe, Ye Xiaofeng, Zhou Mi, Li Haiqing, Qiu Jiapei, Zhao Qiang, Zhu Yunpe |
Abemaciclib plus fulvestrant for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with cystic brain metastases: A case report and literature review. Frontiers in oncology 2022 12 12 984454. Chu Zhaoh |
Intermittent MEK inhibition for the treatment of metastatic uveal melanoma. Frontiers in oncology 2022 10 12 975643. Khan Shaheer, Patel Sapna P, Shoushtari Alexander N, Ambrosini Grazia, Cremers Serge, Lee Shing, Franks Lauren, Singh-Kandah Shahnaz, Hernandez Susana, Sender Naomi, Vuolo Kristina, Nesson Alexandra, Mundi Prabhjot, Izar Benjamin, Schwartz Gary K, Carvajal Richard |
Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase. Clinical pharmacology and therapeutics 2022 Jul . Combes François Pierre, Li Ying Fei, Hoch Matthias, Lorenzo Sebastien, Ho Yu-Yun, Sy Sherwin K |
Randomized phase-III study of low-dose cytarabine and etoposide?+?/- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia. Scientific reports 2023 9 13 (1): 14809. R F Schlenk, D Weber, J Krzykalla, T Kindler, G Wulf, B Hertenstein, H R Salih, T Südhoff, J Krauter, U Martens, S Wessendorf, V Runde, H J Tischler, M Bentz, E Koller, M Heuser, F Thol, A Benner, A Ganser, K Döhner, H Döhn |
The impact of body image dissatisfaction on psychological distress and health-related quality of life among patients in methadone treatment. The American journal on addictions 2023 5 . Meagan M Carr, Zachary L Mannes, Lindsay M S Oberleitner, David E Oberleitner, Mark Beitel, Marina G Gazzola, Lynn M Madden, Xiaoying Zheng, Declan T Bar |
Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study. BMC cancer 2023 4 23 (1): 331. Hu Xingsheng, Cui Xinge, Wang Ziping, Liu Yunpeng, Luo Ying, Zhong Wei, Zhao Hui, Yao Mengxing, Jiang Da, Wang Mingxia, Chen Minjiang, Zheng Xin, Ding Lieming, Wang Yang, Yuan Xiaobin, Wu Pengxiang, Hu Bei, Han Xiaohong, Shi Yuank |
AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20). The oncologist 2023 4 . Suh Koung Jin, Ryu Min-Hee, Zang Dae Young, Bae Woo Kyun, Lee Hye Seung, Oh Hyeon Jeong, Kang Minsu, Kim Ji-Won, Kim Bum Jun, Mortimer Peter G S, Kim Hee Jung, Lee Keun-Wo |
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. European journal of cancer (Oxford, England : 1990) 2023 3 184 39-47. Robson Mark E, Im Seock-Ah, Senkus Elzbieta, Xu Binghe, Domchek Susan M, Masuda Norikazu, Delaloge Suzette, Tung Nadine, Armstrong Anne, Dymond Mike, Fielding Anitra, Allen Allison, Conte Pierfran |
Poziotinib in Treatment-Naïve Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-label Phase 2 Trial (Cohort 4). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2023 3 . Cornelissen Robin, Prelaj Arsela, Sun Sophie, Baik Christina, Wollner Mirjana, Haura Eric B, Mamdani Hirva, Riess Jonathan W, Cappuzzo Federico, Garassino Marina C, Heymach John V, Socinski Mark A, Leu Szu-Yun, Bhat Gajanan, Lebel Francois, Le Xiuning, |
Physiologically-based pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles. Toxicology and applied pharmacology 2023 3 466 116475. Gong Fei, Hu Huihui, Ouyang Ying, Liao Zheng-Zheng, Kong Ying, Hu Jin-Fang, He Hua, Zhou Yi |
Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial. EClinicalMedicine 2023 10 64 102238. Si-Yang Maggie Liu, Xiao-Rong Dong, Zhen Wang, Yingying Du, Jiu-Wei Cui, Qian Chu, Bing-Fei Xu, Ming-Ying Zheng, Jia-Yi Deng, Chang Lu, Xue-Wu Wei, Yang-Si Li, Mei-Mei Zheng, Ming-Yi Yang, Jie Huang, Anna Li, Xiao-Yan Bai, Yue-Li Sun, Chong-Rui Xu, Bin-Chao Wang, Hua-Jun Chen, Jin-Ji Yang, Hong-Hong Yan, Wen-Zhao Zhong, Qing Zhou, Yi-Long |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: